|
LCOR expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.99149999613857E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.52930000000473E-05 |
| Normal-vs-Stage2 |
2.12479999994741E-06 |
| Normal-vs-Stage3 |
1.56730000089311E-08 |
| Normal-vs-Stage4 |
3.28920000014499E-07 |
| Stage1-vs-Stage2 |
1.293830E-01 |
| Stage1-vs-Stage3 |
3.637800E-02 |
| Stage1-vs-Stage4 |
4.180000E-02 |
| Stage2-vs-Stage3 |
8.815400E-01 |
| Stage2-vs-Stage4 |
6.676000E-01 |
| Stage3-vs-Stage4 |
7.406600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.84579999460166E-08 |
| Normal-vs-AfricanAmerican |
4.898100E-02 |
| Normal-vs-Asian |
3.99810000000222E-05 |
| Caucasian-vs-AfricanAmerican |
1.606030E-01 |
| Caucasian-vs-Asian |
8.031000E-01 |
| AfricanAmerican-vs-Asian |
1.899250E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.67690022662748E-10 |
| Normal-vs-Female |
1.78399999994916E-06 |
| Male-vs-Female |
3.744300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.410100E-04 |
| Normal-vs-Age(41-60Yrs) |
8.56199999788032E-08 |
| Normal-vs-Age(61-80Yrs) |
6.49029996413475E-09 |
| Normal-vs-Age(81-100Yrs) |
4.416700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.656300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.409770E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.794400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.742000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.356200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.367600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.212400E-04 |
| Classical-VS-Follicular |
1.627170E-01 |
| Classical-VS-Other |
1.494370E-01 |
| Classical-VS-Normal |
4.29400000001579E-06 |
| Tall-VS-Follicular |
7.443800E-02 |
| Tall-VS-Other |
8.037800E-01 |
| Tall-VS-Normal |
4.27419999393663E-09 |
| Follicular-VS-Other |
3.754800E-01 |
| Follicular-VS-Normal |
4.11499999997123E-06 |
| Other-VS-Normal |
2.141700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.15840000211887E-08 |
| Normal-vs-N1 |
3.09300000000956E-06 |
| N0-vs-N1 |
6.491200E-01 |
|
|
